{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:15:26Z","timestamp":1791260126024,"version":"4.1.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Optimal pharmacotherapy in pediatric patients with suspected infections requires understanding and integration of relevant data on the antibiotic, bacterial pathogen, and patient characteristics. Because of age-related physiological maturation and non-maturational covariates (e.g., disease state, inflammation, organ failure, co-morbidity, co-medication and extracorporeal systems), antibiotic pharmacokinetics is highly variable in pediatric patients and difficult to predict without using population pharmacokinetics models. The intra- and inter-individual variability can result in under- or overexposure in a significant proportion of patients. Therapeutic drug monitoring typically covers assessment of pharmacokinetics and pharmacodynamics, and concurrent dose adaptation after initial standard dosing and drug concentration analysis. Model-informed precision dosing (MIPD) captures drug, disease, and patient characteristics in modeling approaches and can be used to perform Bayesian forecasting and dose optimization. Incorporating MIPD in the electronic patient record system brings pharmacometrics to the bedside of the patient, with the aim of a consisted and optimal drug exposure. In this narrative review, we evaluated studies assessing optimization of antibiotic pharmacotherapy using MIPD in pediatric populations. Four eligible studies involving amikacin and vancomycin were identified from 418 records. Key articles, independent of year of publication, were also selected to highlight important attributes of MIPD. Although very little research has been conducted until this moment, the available data on vancomycin indicate that MIPD is superior compared to conventional dosing strategies with respect to target attainment. The utility of MIPD in pediatrics needs to be further confirmed in frequently used antibiotic classes, particularly aminoglycosides and beta-lactams.<\/jats:p>","DOI":"10.3389\/fped.2021.624639","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T23:44:22Z","timestamp":1614037462000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Alan","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elma","family":"Edwina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno D.","family":"Wildschut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"de Hoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1542\/peds.2010-1275","article-title":"Variability in antibiotic use at children's hospitals","volume":"126","author":"Gerber","year":"2010","journal-title":"Pediatrics."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e20181056","DOI":"10.1542\/peds.2018-1056","article-title":"Antibiotic prescribing for children in United States emergency departments: 2009\u20132014","volume":"143","author":"Poole","year":"2019","journal-title":"Pediatrics."},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2471\/BLT.16.176123","article-title":"Use of antibiotics in children younger than two years in eight countries: a prospective cohort study","volume":"95","author":"Rogawski","year":"2017","journal-title":"Bull World Health Organ."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1097\/INF.0b013e318286c612","article-title":"The antibiotic resistance and prescribing in european children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide","volume":"32","author":"Versporten","year":"2013","journal-title":"Pediatr Infect Dis J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","article-title":"What is the right dose for children?","volume":"70","author":"Cella","year":"2010","journal-title":"Br J Clin Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","article-title":"Tips and traps analyzing pediatric PK data","volume":"21","author":"Anderson","year":"2011","journal-title":"Paediatr Anaesth."},{"key":"B7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jcph.585","article-title":"Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling","volume":"56","author":"Upreti","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1002\/jcph.1483","article-title":"Ontogeny of phase i metabolism of drugs","volume":"59","author":"Allegaert","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-19.4.262","article-title":"Developmental pharmacokinetics in pediatric populations","volume":"19","author":"Lu","year":"2014","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.jinf.2013.09.011","article-title":"Neonatal sepsis: progress towards improved outcomes","volume":"68","author":"Shane","year":"2014","journal-title":"J Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1128\/CMR.00031-13","article-title":"Early-onset neonatal sepsis","volume":"27","author":"Simonsen","year":"2014","journal-title":"Clin Microbiol Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fped.2015.00060","article-title":"The human neonatal gut microbiome: a brief review","volume":"3","author":"Gritz","year":"2015","journal-title":"Front Pediatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5863\/1551-6776-15.2.94","article-title":"Pharmacokinetics and drug dosing in obese children","volume":"15","author":"Kendrick","year":"2010","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11095-016-2033-y","article-title":"Clinical pharmacology studies in critically ill children","volume":"34","author":"Thakkar","year":"2017","journal-title":"Pharm Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","article-title":"Inflammation and organ failure severely affect midazolam clearance in critically ill children","volume":"194","author":"Vet","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/IDR.S171669","article-title":"Extremely high levels of vancomycin can cause severe renal toxicity","volume":"11","author":"Barcel\u00f3-Vidal","year":"2018","journal-title":"Infect Drug Resist."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1128\/JCM.01949-09","article-title":"Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin","volume":"48","author":"Welsh","year":"2010","journal-title":"J Clin Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e26.2\u2013e26","DOI":"10.1136\/archdischild-2019-esdppp.61","article-title":"Evaluation of exposure to vancomycin in neonates with current dosing approaches","volume":"104","author":"Dao","year":"2019","journal-title":"Arch Dis Child."},{"key":"B22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","article-title":"Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)","volume":"24","author":"Abdulla","year":"2020","journal-title":"Crit Care."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/jac\/dkp085","article-title":"Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations","volume":"63","author":"Thomson","year":"2009","journal-title":"J Antimicrob Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"73","author":"Roberts","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0924-8579(02)00188-7","article-title":"TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients","volume":"20","author":"Pea","year":"2002","journal-title":"Int J Antimicrob Agents."},{"key":"B26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/imj.12036","article-title":"Vancomycin therapeutics and monitoring: a contemporary approach","volume":"43","author":"Avent","year":"2013","journal-title":"Intern Med J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","article-title":"Model-informed precision dosing at the bedside: scientific challenges and opportunities","volume":"7","author":"Keizer","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/j.1365-2125.2012.04406.x","article-title":"External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings","volume":"75","author":"Zhao","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e28132","DOI":"10.1002\/pbc.28132","article-title":"Pharmacokinetics and population pharmacokinetics in pediatric oncology","volume":"67","author":"Sassen","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1200\/JCO.1993.11.12.2314","article-title":"Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula","volume":"11","author":"Newell","year":"1993","journal-title":"J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0009-9236(96)90113-7","article-title":"Population pharmacokinetics of carboplatin in children","volume":"59","author":"Chatelut","year":"1996","journal-title":"Clin Pharmacol Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1365-2125.2005.02533.x","article-title":"A Bayesian approach for population pharmacokinetic modelling of sirolimus","volume":"62","author":"Dansirikul","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cpt.1679","article-title":"Development and implementation of electronic health record\u2013integrated model-informed clinical decision support tools for the precision dosing of drugs","volume":"107","author":"Vinks","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40262-018-00732-2","article-title":"Personalized tuberculosis treatment through model-informed dosing of rifampicin","volume":"58","author":"van Beek","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5195\/JMLA.2017.111","article-title":"Reviewing retrieved references for inclusion in systematic reviews using endnote","volume":"105","author":"Bramer","year":"2017","journal-title":"J Med Libr Assoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1128\/AAC.01157-15","article-title":"Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice","volume":"59","author":"Smits","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1128\/AAC.02214-15","article-title":"Clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates","volume":"60","author":"Leroux","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jpids\/pix109","article-title":"Individualized empiric vancomycin dosing in neonates using a model-based approach","volume":"8","author":"Frymoyer","year":"2019","journal-title":"J Pediatric Infect Dis Soc."},{"key":"B42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jac\/dkz444","article-title":"Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population","volume":"75","author":"Hughes","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"104278","DOI":"10.1016\/j.phrs.2019.104278","article-title":"Optimisation of vancomycin exposure in neonates based on the best level of evidence","volume":"154","author":"Dao","year":"2020","journal-title":"Pharmacol Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/j.1875-9114.2012.01029.x","article-title":"Evaluation of vancomycin dosing regimens in preterm and term neonates using monte carlo simulations","volume":"32","author":"Mehrotra","year":"2012","journal-title":"Pharmacotherapy."},{"key":"B45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40272-020-00400-8","article-title":"External validation of model-based dosing guidelines for vancomycin, gentamicin, and tobramycin in critically ill neonates and children: a pragmatic two-center study","volume":"22","author":"Hartman","year":"2020","journal-title":"Pediatr Drugs."},{"key":"B46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/11595640-000000000-00000","article-title":"Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance","volume":"51","author":"De Cock","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/cpt.202","article-title":"Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children","volume":"98","author":"Savic","year":"2015","journal-title":"Clin Pharmacol Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/clpt.2014.134","article-title":"Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents","volume":"96","author":"Gonzalez","year":"2014","journal-title":"Clin Pharmacol Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/archdischild-2012-302765","article-title":"Vancomycin continuous infusion in neonates: Dosing optimisation and therapeutic drug monitoring","volume":"98","author":"Zhao","year":"2013","journal-title":"Arch Dis Child."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections","volume":"32","author":"Frymoyer","year":"2013","journal-title":"Pediatr Infect Dis J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40121-015-0067-9","article-title":"Predictive performance of a vancomycin population pharmacokinetic model in neonates","volume":"4","author":"Stockmann","year":"2015","journal-title":"Infect Dis Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1542\/peds.103.4.e48","article-title":"Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study","volume":"103","author":"Bhatt-Mehta","year":"1999","journal-title":"Pediatrics."},{"key":"B54","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.ejps.2017.05.037","article-title":"Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies","volume":"109","author":"Mizuno","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.bbmt.2017.06.021","article-title":"Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients","volume":"23","author":"Ivaturi","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B56","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00665","article-title":"Precision dosing of doxapram in preterm infants using continuous pharmacodynamic data and model-based pharmacokinetics: an illustrative case series","volume":"11","author":"Poppe","year":"2020","journal-title":"Front Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00888","article-title":"Assessment of a model-informed precision dosing platform use in routine clinical care for personalized busulfan therapy in the pediatric hematopoietic cell transplantation (HCT) population","volume":"11","author":"Shukla","year":"2020","journal-title":"Front Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/pbc.22467","article-title":"Comparison of two methods for carboplatin dosing in children with retinoblastoma","volume":"55","author":"Allen","year":"2010","journal-title":"Pediatr Blood Cancer."},{"key":"B60","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40262-014-0135-4","article-title":"Evidence-based morphine dosing for postoperative neonates and infants","volume":"53","author":"Krekels","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/FTD.0000000000000763","article-title":"Model-informed bayesian estimation improves the prediction of morphine exposure in neonates and infants","volume":"42","author":"Euteneuer","year":"2020","journal-title":"Ther Drug Monit."},{"key":"B62","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/cpt.1957","article-title":"MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase","volume":"108","author":"Taylor","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/aps.2016.163","article-title":"Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement","volume":"38","author":"Zhu Bin","year":"2017","journal-title":"Acta Pharmacol Sin."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00794","article-title":"Individualized dosing with high inter-occasion variability is correctly handled with model-informed precision dosing\u2014using rifampicin as an example","volume":"11","author":"Keutzer","year":"2020","journal-title":"Front Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fphar.2020.00283","article-title":"Integrated data analysis of six clinical studies points toward model-informed precision dosing of tamoxifen","volume":"11","author":"Klopp-Schulze","year":"2020","journal-title":"Front Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0009-9236(98)90100-X","article-title":"What are narrow therapeutic index drugs?","volume":"63","author":"Levy","year":"1998","journal-title":"Clin Pharmacol Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/A:1008829403320","article-title":"Management of narrow therapeutic index drugs","volume":"7","author":"Burns","year":"1999","journal-title":"J Thromb Thrombolysis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1365-2125.2001.0520s1035.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52","author":"Begg","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e77169","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS ONE."},{"key":"B71","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/491712","article-title":"The Pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3138\/jammi.2018.09.19","article-title":"Aminoglycosides-alive and well in treatment of pediatric infections: a case of benefit versus risk","volume":"4","author":"Le Saux","year":"2019","journal-title":"Off J Assoc Med Microbiol Infect Dis Canada."},{"key":"B74","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fncel.2017.00325","article-title":"Towards the prevention of aminoglycoside-related hearing loss","volume":"11","author":"O'Sullivan","year":"2017","journal-title":"Front Cell Neurosci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"Van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1128\/AAC.00577-16","article-title":"Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants","volume":"60","author":"Germovsek","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B77","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fphar.2020.00551","article-title":"Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children's hospital","volume":"11","author":"Frymoyer","year":"2020","journal-title":"Front Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fphar.2020.00646","article-title":"Right dose, right now: development of autokinetics for real time model informed precision antibiotic dosing decision support at the bedside of critically ill patients","volume":"11","author":"Roggeveen","year":"2020","journal-title":"Front Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bcp.14426","article-title":"Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care","author":"Mizuno","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.624639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:25:43Z","timestamp":1666769143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.624639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":81,"alternative-id":["10.3389\/fped.2021.624639"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.624639","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"article-number":"624639"}}